TC
CLDX icon

T3 Companies’s Celldex Therapeutics CLDX Stock Holding History

T3 Companies’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
+6,000
New +$194K 0.24% 85

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T3 Companies's CLDX Position: Q2 2026 in Review

T3 Companies opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 6,000 shares worth $223K. The stake represents 0.24% of the portfolio and ranks #85 among its holdings.

252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • T3 Companies held 6,000 shares of Celldex Therapeutics worth $223K as of Q2 2026.
  • Celldex Therapeutics was a new T3 Companies position in Q2 2026.
  • Celldex Therapeutics made up 0.24% of T3 Companies's portfolio in Q2 2026, its #85 holding.
  • 252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.